Tetrazine-Enabled Peptide Macrocyclization and Bioorthogonal Cell Penetration Profiling Authors: Hao Liu, Hui Xu, Lei Yang, Dan Zhang, Yanjun Wang, Jieting Shen, Xinyun Ma, Jiaxiang Wang, Yangyang Kong, Xian Jia, Kuan Hu, Rui Wang, Luping Liu Published: 2026 ABSTRACT Cyclization of linear peptides into macrocyclic structures confers superior properties such as improved membrane permeability and proteolytic stability while maintaining high target affinity and specificity toward protein targets. Here, we present a cysteine-selective macrocyclization strategy that employs an alkylating motif of chloroethyl tetrazine to react with the thiol side chain in unprotected peptides. This approach efficiently yields cyclic peptides bearing bioorthogonal tetrazine handles, enabling precise late-stage modification via robust tetrazine ligations. We applied this method to synthesize and screen rofapitide tetraxetan analogues, identifying a novel peptide 2o, which exhibits potent binding to cancer-associated fibroblast activation protein (FAP) both in vitro and in vivo. Furthermore, we developed an innovative bioorthogonal cell penetration assay (BCPA) based on a “click-to-release” reaction between the tetrazine-containing peptide (Tz-Pep) and a trans-cyclooctene-caged Nile Blue dye (TCO-Nile Blue) to liberate fluorescent Nile Blue, allowing quantitative evaluation of peptide internalization in living cells. We anticipate that this tetrazine-mediated cyclization strategy and cell penetration assay will find wide applications in biological research and drug discovery. Introduction Peptides are recognized as important therapeutic agents and research tools due to their high specificity, safety, and synthetic accessibility. , However, their biological and medicinal applications are hampered by inherent drawbacks, such as poor metabolic stability and low membrane permeability. Cyclization offers a promising strategy to overcome these limitations. By reducing conformational flexibility, cyclic peptides exhibit enhanced proteolytic stability and improved cell permeability while maintaining binding affinity. While classical cyclization methods include lactamization and disulfide bond formation, recent advances have introduced diverse linkers for constructing cyclic peptides. , The linking strategy primarily involves bridging the nucleophilic thiol side chains of cysteine residues in linear peptide precursors. For instance, phage display technology has enabled the generation of macrocyclic and bicyclic peptide libraries by coupling cysteine residues with di- or trisubstituted benzyl halides. , Thiol-fluoroaryl-linked cyclic peptides, in particular, have demonstrated significantly improved membrane permeability. Beyond cysteine, other amino acids with reactive side chainssuch as lysine, , tyrosine, tryptophan and serinehave also been utilized in peptide macrocyclization. Moreover, non-natural amino acids have been incorporated via click chemistry, ring-closing metathesis (RCM), and other orthogonal reactions. , Despite tremendous progress, the development of new macrocyclization methods remains highly valuable to meet diverse research and therapeutic needs. In recent years, multifunctional coupling reagents have emerged as powerful tools for constructing macrocyclic peptides, thereby diversifying their structures and activities. − By incorporating bioorthogonal tags into the cyclization linkage, efficient late-stage modular modifications of cyclic peptides have been developed. Among various bioorthogonal reactions, the inverse electron-demand Diels–Alder (IEDDA) cycloaddition between tetrazines (Tz) and dienophiles has gained increasing attention due to its prominent rapid kinetics, high biocompatibility, and catalyst-free nature. In view of the electron-deficient character of aromatic tetrazine rings, 3,6-dichlorotetrazine was employed as a coupling reagent for cysteine residues in linear peptides. However, the resulting S,S-tetrazine-containing cyclic peptides showed poor biocompatibility, as they were prone to reversible thiol exchange reaction or photolysis. Subsequent efforts utilized methyl sulfide tetrazines for macrocyclization via rapid tetrazine–thiol exchange with cysteine, although the reversible S-tetrazine linkages could be suppressed after an IEDDA cycloaddition with trans-cyclooctene (TCO). , Notably, an elegant Tz-substituted allyl acetate linker has been recently developed for macrocyclization via double Michael cascade reactions with cysteines. Our group has been interested in the kinetic control of tetrazine reactivity. , To our surprise, compared with well-established dichlorotetrazine and sulfide tetrazine in peptide chemistry, haloalkyl tetrazine compounds remain underdeveloped. However, we hypothesized that the electron-withdrawing effect of the aromatic tetrazine moiety could activate the adjacent alkyl halide, thereby enabling selective cross-linking of cysteine residue. Importantly, the resulting S-alkyl tetrazine may exhibit better biostability compared to S-tetrazine, facilitating its biological and medicinal applications. To test this hypothesis, we synthesized and evaluated several haloalkyl tetrazines; ultimately, chloroethyl tetrazine was chosen for its dual functionality for peptide macrocyclization while preserving bioorthogonal reactivity. We have demonstrated this approach in the late-stage modification of cyclic peptides and the fast, high-yielding “click” reactions between tetrazines and dienophile-modified bioactive molecules, enabling various structural diversification and functionalization. Moreover, we aimed to expand the applications of tetrazine chemistry in peptides. Given the crucial importance of cell permeability for peptide therapeutics, we proposed a fluorogenic activation between tetrazine and trans-cyclooctene-modified dye, which may provide a facile bioorthogonal cell penetration assay (BCPA) to quantitatively evaluate the cellular peptides. Results and Discussion Chloroalkyl Tetrazine-Mediated Peptide Macrocyclization Above all, the chemoselective reactivity of chloroalkyl tetrazine toward cysteine is crucial for the anticipated S-alkyl tetrazine-linked cyclic peptides in our design. Considering this, we first designed and synthesized three different chloroalkyl tetrazines at the beginning of this study (see Supporting Information synthetic methods): chloromethyl phenyl tetrazine (1a), chloroethyl phenyl tetrazine (1b), and chloropropyl phenyl tetrazine (1c). Hence, the effect of varying the length of alkyl groups has been examined (Figure A). The chloroalkyl tetrazine of 1 was incubated with a mixture of nucleophilic amino acids (including cysteine, tyrosine, histidine, arginine, serine, and lysine) in a slightly basic PBS buffer (pH = 8) to promote the anticipated nucleophilic reaction. However, the chloromethyl phenyl tetrazine 1a was dramatically degraded to 2-methyl-5-phenyl-1,3,4-oxadiazole under the reaction conditions and only 10% yield of cysteine-specific product 2a was observed after 12 h. To our delight, the reaction of chloroethyl phenyl tetrazine (1b) proceeded well under the same conditions. The desired cysteine-selective product of 2b was obtained with a high yield of 81%, even in the presence of other highly reactive amino acid residues such as tyrosine, histidine, arginine, serine, and lysine. In comparison, 1c proved to be inert in the mixture of reactive amino acids, and no product 2c was detected after 12 h, which indicated that the diminishing electron-withdrawing effect of the tetrazine was insufficient to activate the chloro group at γ position. Encouraged by the promising result from 1b in Figure A, we sought to explore the reaction of chloroethyl phenyl tetrazine with the cysteine residue in the peptide. Thus, a model linear peptide of 1d was prepared accordingly and the reaction conditions have been optimized (Table S8). Due to the poor aqueous solubility, methanol (MeOH) containing 1% dimethylformamide (DMF) was employed to dissolve 1d. The intramolecular cyclization reaction proceeded well in the mixture of MeOH and PBS (pH = 7.4) affording the desired S-ethyl tetrazine-tethered cyclic peptide 2d in a high yield of 86% at 37 °C after 3 h. Under basic conditions (pH = 8.0), an almost quantitative conversion (99%) was observed (Figure B). Encouraged by these results, we investigated the mechanism underlying the chloroethyl tetrazine-mediated peptide macrocyclization. In addition to our proposed nucleophilic substitution reaction, a possible intermediate of vinyl tetrazine via elimination may occur, followed by a Michael addition with cysteine. For this reason, kinetic analysis of model linear peptide (1d) in the mixture of MeOH and PBS (pH = 7.4 or 8.0) for 3 h was conducted by HPLC; however, no detectable vinyl tetrazine was observed. Then, further kinetic analysis of chloroethyl phenyl tetrazine (1b) was conducted alone under the above conditions. As shown in Figure S21, a significant amount of vinyl phenyl tetrazine was generated from 1b in the mixture of MeOH and PBS, and the yields of the elimination product were 44% (pH = 7.4) and 97% (pH = 8.0), respectively. Based on these findings, we hypothesized that elimination and nucleophilic substitution proceeded concurrently at comparable rates under neutral condition (pH = 7.4). However, the chloroethyl tetrazine predominantly underwent elimination under basic conditions (pH = 8.0), with a subsequent Michael addition to cysteine yielding the cyclic peptide 2d. Chloroalkyl tetrazine-mediated cyclization with unprotected peptides. A) Cysteine-selective reaction of chloroalkyl tetrazines in the presence of multiple nucleophilic amino acids: A solution of 1 (50 μM), cysteine (200 μM) and mixed amino acids including tyrosine, lysine, histidine, arginine, and serine (500 μM each) was incubated in PBS (20 mM, pH = 8.0) at 37 °C for 12 h. aHPLC yields were based on HPLC analysis of the reaction mixture by integrating UV absorptions of peptide-related peaks at 270 nm. N.R., no reaction. B) Intramolecular cyclization of linear peptide 1d. C) Chloroethyl tetrazine-mediated macrocyclizations in unprotected peptides bearing various amino acid residues and lengths. The reaction was conducted by incubating 1 in a solution of methanol containing 0.3% DIPEA at 37 °C for 3 h. bIsolated yield by semipreparative HPLC. cThe reaction was conducted by incubating 1f in a solution of methanol containing 0.5% DIPEA at 37 °C for 6 h. With the optimized reaction conditions in hand, we next explored the reaction scope. To demonstrate the generality of this cysteine-selective macrocyclization in unprotected peptides, a wide range of linear peptides (1e–l) with varying lengths, constituents, and sequences were prepared by the solid-phase peptide synthesis (SPPS). A linear peptide 1e with exposed C-terminal and reactive side chains was examined initially. Happily, the cysteine-specific macrocyclization worked well, affording the desired 2e in an excellent isolated yield of 94%. Since glutamic acid, lysine and methionine did not significantly affect the yield of 2e, we were encouraged to extend this methodology to construct various bioactive cyclic peptides, such as targeting peptide (KKD-m1, M1, RPMrel, rofapitide tetraxetan, and RGD), cytotoxic peptide (Phakellistatin 13), and antibiotic peptide (Temporin-1p). As shown in Figure C, this chloroethyl tetrazine-mediated intramolecular macrocyclization was quite effective, and the anticipated S-ethyl tetrazine-linked bioactive peptide analogues (2f–l) were obtained in good to excellent isolated yields (71–97%) with slightly modified reaction conditions such as increasing reaction concentration and the amount of DIPEA. It is worth noting that highly reactive amino acid residues (including serine, threonine, arginine, histidine, tryptophan, and aspartic acid) were well tolerated in this protocol and did not affect the cysteine-specific reaction. Overall, this chloroethyl tetrazine-mediated peptide macrocyclization exhibited excellent chemoselectivity and high yield, affording various stable S-ethyl tetrazine-linked cyclic peptides. “One-Pot” Peptide Cyclization and Late-Stage Functionalization Although macrocyclization was successfully achieved in unprotected peptides (Figure ), a preinstallation of unnatural amino acid-bearing chloroethyl phenyl tetrazine into linear peptides was necessary. To optimize this method, we further designed and synthesized an “all in one” linker of NHS ester-modified chloroethyl phenyl tetrazine 1m (Figure A). Hence, a linear peptide with a sequence of LIGANDC was chosen as a standard substrate. Following SPPS synthesis, the crude peptide LIGANDC was incubated with 2 equiv of 1m (calculated on the basis of the degree of substitution of the resin) in pyridine at 60 °C for 30 min. Then the resulting tetrazine-containing LIGANDC was treated in MeOH (containing 0.3% DIPEA) at 37 °C for 3 h for macrocyclization. Later, 1.5 equiv of functional-group-modified dienophile was added for the subsequent bioorthogonal ligations with the obtained cyclic peptide c­(Tz-LIGANDC), resulting in structural diversification and functionalization of cyclic peptides (3a–f) in one pot. “One-Pot” peptide cyclization and late-stage functionalization. A) Schematic illustration of the synthesis of tetrazine-containing cyclic peptides from resin and subsequent postmodification through tetrazine ligations. The linear unprotected peptides were prepared using solid-phase peptide synthesis (SPPS). A peptide cyclizing agent of NHS ester-modified chloroethyl tetrazine (1m) was added. Upon the completion of peptide macrocyclization, functionalized dienophile was added, resulting in structural diversification and functionalization of cyclic peptides. B) Bioorthogonal functionalization of macrocyclic peptides in the late-stage. aIsolated yield calculated on the basis of the degree of substitution of the resin. In this study, we have incorporated a bioorthogonal tetrazine tag into the cyclization linkage, which served as a facile reactive handle for the subsequent introduction of functional modules. Having established the chloroethyl tetrazine-mediated peptide macrocyclization, we next explored bioorthogonal modification of peptides in the late stage. Because of their rapid kinetics, dienophiles of trans-cyclooctene (TCO) and bicycle[6.1.0]­nonyne (BCN) were chosen in our study. As shown in Figure B, various functional-group-modified dienophiles have been examined. For example, since glucamine could specifically accumulate at tumor sites due to the overexpressed GLUT1 in tumors, we reacted the model peptide c­(Tz-LIGANDC) with a TCO-glucamine. As expected, the conjugated product of 3a with potentially enhanced tumor targeting was obtained in a good yield of 42% based on resin. Encouragingly, we extended this strategy to incorporate a cytotoxic agent, thus, monomethyl auristatin E (MMAE), widely used in peptide–drug conjugates (PDCs), was introduced via an BCN-modified MMAE (3b, 38% yield). Moreover, BCN-DOTA was also well-tolerated in our protocol, generating DOTA-modified cyclic peptide 3c in a good yield of 69%. A lipid tail was appended (3d, 28% yield) to improve the membrane permeability and prolong plasma half-life time. Finally, tetrazine-containing cyclic peptides were successfully modified with chemical tags such as biotin (3e, 42% yield) and pomalidomide (3f, 47% yield), providing versatile tools for chemical biology and medicinal studies. Overall, we have shown a facile and efficient one-pot peptide cyclization and late-stage functionalization, which provide versatile tools for modular peptide drug development. Bioactivity Evaluation of Cyclic Tetrazine Rofapitide Tetraxetan Analogues After demonstration of the macrocyclization efficiency, we further evaluated the biological activity of cyclic tetrazine peptides. Fibroblast activation protein (FAP) is a transmembrane glycoprotein receptor critical for extracellular matrix (ECM) remodeling, which promotes tumor cell invasion and metastasis. Notably, the cyclic peptide rofapitide tetraxetan has been validated as a specific FAP-targeting ligand, with the sequence CPPTQFC identified as the core bioactive motif responsible for mediating FAP-binding affinity and targeted recognition. Based on this CPPTQFC core motif, we first synthesized the parent peptide 2m (Hex-(Cys­(dMeBn)-PPTQFC)–OH) via cyclization of the CPPTQFC sequence using 1,3-bis­(bromomethyl)­benzene as the cross-linker. Its equilibrium dissociation constant (K D) value for recombinant human FAP was determined to be 157 nM by surface plasmon resonance (SPR) (Figure S76). We then designed and synthesized peptides 2n–2p using our one-pot cyclic tetrazine peptide synthesis strategy for screening, aiming to identify candidates with promising bioactivity potential. These analogues were derived from 2m by substituting the N-terminal alkyl moiety with an l-norleucine (Nle) residue and extending the N-terminus with 1–3 glycine residues to alleviate the conformational constraints imposed by the tetrazine ring. We further evaluated the binding affinity of 2n–p toward FAP via SPR. The results confirmed that all three analogues bind to FAP, with K D values of 427 nM, 53 nM and 3 μM, respectively (Figure B, Figure S76). To our delight, 2o exhibited excellent binding affinity, which is 3-fold greater than that of 2m. Comparison of SPR sensorgrams for 2m and 2o revealed that the improved affinity of 2o is primarily attributed to a slower dissociation rate. Specifically, the dissociation rate constant (k d) of 2o is 4.46 × 10–2 s–1, 5-fold lower than that of 2m (k d = 2.22 × 10–1 s–1) (Figure S76). Bioactivity evaluation of cyclic tetrazine rofapitide tetraxetan analogues in vitro. A) SPR-determined binding affinities of rofapitide tetraxetan analogues to FAP. 2m was cyclized from the CPPTQFC sequence using 1,3-bis­(bromomethyl)­benzene, while 2n–t are derivatives cyclized via chloroethyl tetrazine. B) SPR characterization of the binding affinity of 2o to FAP. C) Confocal fluorescence images showing 2o binding to cell-surface FAP on HT1080-FAP cells. 2o was visualized via inverse electron-demand Diels–Alder (IEDDA) ligation with TCO-Cy5 (red). Top row: Representative images of HT1080-FAP cells treated with 0.5 μM 2o. Bottom row: Vehicle control-treated HT1080-FAP cells. AF488-conjugated wheat germ agglutinin (AF488-WGA, green) was used for cell membrane staining; cell nuclei were stained with Hoechst 33342 (blue). Scale bar = 10 μm. D) Flow cytometry histograms and E) quantified mean fluorescence intensity (MFI) of HT1080-FAP cells after incubation with or without 0.5 μM 2o (1 h), followed by 0.5 μM TCO-Cy5 incubation (30 min). Data are presented as mean ± standard error of the mean (SEM) (n = 3 independent experiments, two-tailed t test, **** p < 0.0001). To further clarify whether the alkane side chain of the Nle residue in 2o is essential for FAP binding, we designed and synthesized analogues 2q and 2r, in which Nle was replaced with alanine and glycine, respectively. SPR analysis demonstrated that 2q binds FAP with a K D of 517 nM, while 2r displayed significantly attenuated binding affinity with a K D value of 3180 nM. These results confirm that retention of an optimal alkyl chain length at this specific position facilitates peptide-FAP binding interactions. We then extended this structure–activity relationship (SAR) study to explore whether the position of the Nle residue in 2o is crucial for its binding activity. To this end, we synthesized analogues by installing the Nle residue to the N-terminus or its adjacent position (2s and 2t). SPR analysis showed that both analogues exhibited dramatically reduced FAP-binding activity (Figure S76). Collectively, these findings illustrate that the specific position of the Nle residue in 2o is critical for sustaining high-affinity binding to the FAP. Rofapitide tetraxetan has been shown to bind specifically to FAP on the cell surface with a substantial binding affinity. To validate the FAP-binding capacity of 2o at the cellular level, we examined its specific binding to cell-surface FAP using FAP-overexpressing HT1080 (HT1080-FAP) cells and parental HT1080 cells. Confocal fluorescence imaging revealed clear colocalization between fluorescence from WGA-AF488 (a membrane probe targeting cell-surface N-acetylglucosamine and sialic acid) and that from peptide 2o (after TCO-Cy5 treatment) on HT1080-FAP cells (Figure C and Figure S78). These results confirm the specific binding of 2o to FAP on the surface of the HT1080-FAP cells. Flow cytometry analysis further quantified this binding interaction, demonstrating that 2o exhibits specific binding affinity for HT1080-FAP cells, with a mean fluorescence intensity 20-fold higher than that of the control group (Figure E). Taken together, these data demonstrate that cyclic tetrazine peptide 2o possesses potent in vitro FAP-targeting activity. The promising in vitro bioactivity of 2o prompted us to investigate its tumor-targeting capability in vivo by using positron emission tomography/computed tomography (PET/CT) imaging in xenograft tumor models. To this end, we first synthesized conjugate 3g (Figure A) by reacting 2o with BCN-DOTA. SPR analysis revealed that 3g binds to FAP with a K D value of 51 nM (Figure B), nearly identical to that of 2o, indicating that conjugation with BCN-DOTA does not compromise the target binding affinity. Serum stability assessments of the linear peptide of 1o and its analogous cyclic peptides of 2o and 3g were conducted next. As shown in Figure S79, the parental linear peptide of 1o was almost completely degraded within 24 h in serum, while the cyclic peptides 2o and 3g exhibited a serum half-life longer than 48 h, revealing the advantage of the cyclic structures in biostability. Subsequently, we radiolabeled 3g with 68Ga to generate the PET imaging probe [68Ga]3g. Quality control analysis confirmed a radiochemical yield (RCY) of >99% for [68Ga]3g (Figure S80), which meets the rigorous purity standards for in vivo radiopharmaceutical imaging studies. To characterize the in vivo pharmacokinetic profile of [68Ga]3g, we performed PET/CT imaging in healthy mice (Figure C). Quantitative analysis of the imaging data revealed the clearance of [68Ga]3g from the liver, whereas significant accumulation was observed in the kidneys and bladder (Figure C). This distribution pattern is consistent with a renal bladder excretion pathway, which represents the primary clearance mechanism for [68Ga]3g. In vivo assessment of [68Ga]­3g for FAP-targeted tumor PET/CT imaging. A) The structure of 3g, synthesized via the reaction of 2o with BCN-DOTA. B) SPR characterization of the binding affinity of 3g to FAP. C) PET/CT images of [68Ga]3g in HT1080-FAP tumor-bearing BALB/c nude mice (upper panel) and tumor-free control mice (lower panel) at 30, 60, 120, and 240 min postintravenous injection (100 μCi/mice). D) Quantitative analysis of [68Ga]3g uptake in tumors, livers, kidneys, and hearts at the indicated time points postinjection. E) Quantified tumor-to-organ uptake ratios of [68Ga]3g in the liver, kidney, heart, and muscle at 30, 60, 120, and 240 min postinjection. All the data are presented as mean %ID/g ± standard error of the mean (SEM) (n = 3 mice per group). Building on this favorable pharmacokinetic profile of [68Ga]3g, we next assessed its tumor-targeting efficiency in BALB/c nude mice bearing HT1080-FAP xenografts. Intravenous administration of [68Ga]3g enabled clear visualization of tumor lesions via PET/CT imaging at 30, 60, 120, and 240 min postinjection, with consistent and distinct tumor delineation across all time points (Figure C). Quantitative analysis of the imaging data confirmed that tumor tissues exhibited the highest radiotracer uptake throughout the entire time course, reaching 5.58 ± 0.47%ID/g as early as 30 min postinjection (Figure D). Specifically, tumor uptake was more than 6-fold higher than that in the liver and heart, and 5-fold greater than in normal muscle tissue at 30 min postinjection (Figure D). Remarkably, the tumor-to-normal tissue uptake ratio continued to widen over time (Figure E), a trend attributed to efficient clearance of [68Ga]3g from normal tissues while sustaining substantial accumulation in tumor lesions. Overall, these findings demonstrate that [68Ga]3g exhibits high tumor accumulation and minimal off-tumor retention, key characteristics that qualify it as a promising PET imaging probe for FAP-positive tumors, with potential for further development as a radiotheranostic agent for FAP-associated malignancies. Cell Penetration Assay of Peptides via Tetrazine Chemistry A reliable and efficient cellular uptake assay is highly valuable for the development of intracellular peptide drugs. Traditional methods for measuring peptide membrane permeability mainly rely on dye labeling; however, the attached fluorescent molecules may alter the physicochemical properties and binding affinity of native peptides. To address this, a recently developed chloroalkane penetration assay (CAPA) exhibits high-throughput and is compartment-specific, although cells used for CAPA should stably express HaloTag proteins. A reliable and efficient cellular uptake assay is highly valuable for the development of intracellular peptide drugs. In this context, the biorthogonal tetrazine handles in peptides may offer a promising approach to quantify their cellular uptakes without interfering inherent cellular processes. To this end, we designed a fluorogenic reaction between tetrazine-containing peptide (Tz-Pep) and trans-cyclooctene-caged Nile Blue dye (4, TCO-Nile Blue), liberating the fluorescent dye Nile Blue (Figure A). We first investigated a known cell-penetrating peptide R9 and conjugated 4-(6-methyl-1,2,4,5-tetrazin-3-yl)­benzeneacetic acid to its N-terminal, yielding MeTz-R9 (2u). Consequently, the fluorogenic reaction was explored and a maximum fluorescence intensity was observed after mixing MeTz-R9 (2u, 10 μM) with TCO-Nile Blue (4, 1 μM) in Optimal-MEM at 37 °C for 6 h (Figure B). Bioorthogonal cell penetration assay (BCPA). A) Fluorogenic reaction between Tz-Pep and TCO-Nile Blue. B) Fluorescence–time curves of the mixture of MeTz-R9 (2u, 10 μM) with TCO-Nile Blue (4, 1 μM), MeTz-R9 (2u, 10 μM), or TCO-Nile Blue (4, 1 μM) in Optimal-MEM at 37 °C. C) Confocal fluorescence microscopy imaging of HeLa cells that were incubated with (up) or without (down) MeTz-R9 (2u, 10 μM, 4 h), then treated with TCO-Nile Blue (1 μM) for 6 h. Scale bar = 100 μm. D) Schematic illustration of BCPA setup. Cells were treated with Tz-Pep, washed to remove the remaining extracellular peptide, chased with TCO-Nile Blue, and finally analyzed by a plate reader to quantify the fluorescence Intensity of Nile Blue. E) Sequences of tetrazine-containing peptide. MeTz represents 4-(6-Methyl-1,2,4,5-tetrazin-3-yl)­benzeneacetic acid, which is linked to the N-terminus of the peptide via an amide bond. cTz represents cyclic tetrazine peptide. Φ represents naphthylalanine. F) BCPA results for Tz-Pep (2h and 2u–z). Error bars show standard error from three independent experiments. CP50 presented as mean ± SEM from three independent curves obtained from three independent experiments. Meanwhile, almost no fluorescence was detected in controls treated with either 2u or 4 alone. On this basis, we further tested this fluorogenic reaction in living cells and the time-dependent fluorescence was monitored using confocal laser. HeLa cells were incubated with or without 2u (10 μM) and then treated with 1 μM of 4. As shown in the top of Figure C, the combinational treatment of 2u + 4 successfully liberated the fluorophore Nile Blue via bioorthogonal click-to-release reaction and progressive fluorescence intensification was observed up to 6 h. In contrast, cells with 4 alone displayed weak cytoplasmic fluorescence throughout the observation period (Figure C and Figure S93). These findings mechanistically validated the fluorogenic reaction in living cells. Encouraged by these results, we proposed a new method to measure the cell penetration of peptides, termed bioorthogonal cell penetration assay (BCPA) in Figure D. In BCPA, cells were first incubated with a Tz-Pep of interest and then washed to remove extracellular peptide. Subsequently, a certain amount of TCO-Nile Blue was added to initiate the click-to-release reaction with the remaining intracellular Tz-Pep, generating fluorescent Nile Blue. Finally, a high-throughput analysis of cellular fluorescence was conducted in a 96-well plate simultaneously by plate reader, quantifying the extent of penetration. For each 96-well plate, fluorescence was normalized to the untreated control (0%) and the maximum intensity (100%). To assess dose dependence, the mean fluorescence intensity was plotted against the concentration of Tz-Pep. Based on these results, the EC50 curve was generated and the midpoint value, designated CP50, was determined as the concentration yielding half maximal fluorescence intensity under the given experimental conditions. To validate the feasibility of BCPA, we first examined the standard cell-penetrating peptide 2u in HeLa cells. In a 96-well plate with 20,000 cells per well, cells were treated with different concentrations of 2u for 4 h. Then, the excess extracellular peptide was washed out, and 1 μM of TCO-Nile Blue was added for 12–24 h. Notably, the extended incubation time made no difference for the fluorescence intensity for 2u in the BCPA. The experimental results were highly reproducible, indicating the excellent biocompatibility and bioorthogonality. Based on these data, we fit the EC50 curve of 2u (red line, Figure F), which shows an excellent CP50 with 0.22 μM, similar to the outcome using reported CAPA. Subsequently, we investigated the tetrazine-containing cyclic cell-penetrating peptides of 2v and 2x, along with their linear precursors of 2w and 2y, respectively. Using BCPA assay, the CP50 values of 2v (0.23 μM), 2w (0.77 μM), 2x (0.42 μM) and 2y (0.84 μM) have been successfully examined. These results indicated that the cyclic peptides 2v and 2x displayed markedly enhanced membrane permeability compared to their linear counterparts, further demonstrating that the superiority of cyclic architecture for cellular internalization. Having validated BCPA with frequently used cell-penetrating peptides, we next employed this assay for newly synthesized peptide 2h. For comparison, its C-terminally amidated derivative (2z) was examined as well, which should display better membrane permeability owing to the increased overall net positive charge. As expected, 2z exhibited improved cellular uptake with a significantly decreased CP50 of 0.58 μM, compared to that of 2h (2.8 μM, Figure F). Additionally, BCPA for negatively charged cTz-Pep 2i was performed, which revealed poor transmembrane capability even at a high concentration of 80 μM. In brief, we have established an innovative bioorthogonal cell penetration assay, which was quantitative, had high-throughput, and was reliable and practical. Conclusions In summary, we have developed a tetrazine-based versatile method that is applicable to peptide macrocyclization, functionalization, and cell penetration profiling. Our approach relies on a specific cyclization reaction between the nucleophilic thiol group of cysteine and a uniquely designed alkylating motif, namely, chloroethyl tetrazine. This approach offers a robust and efficient access to cyclic peptides that are intrinsically equipped with a bioorthogonal tetrazine handle. We successfully applied this method to the synthesis and screening of various cyclic peptides on the basis of known bioactive peptides. The presence of a tetrazine tag on peptides demonstrates a key advantage, which has been utilized for late-stage structural diversification and functionalization through highly selective IEDDA ligations with various dienophile-modified bioactive molecules, including glycan, lipid, cytotoxin, DOTA, biotin, and pomalidomide. Remarkably, among these newly obtained cyclic peptide constructs, 2o emerged as a particularly promising candidate, exhibiting potent and specific binding affinity toward the highly expressed fibroblast activation protein in cancer. This high affinity was consistently observed across both in vitro assays and complex in vivo models, underscoring their potential for therapeutic or diagnostic applications. We anticipate that this tetrazine-based peptide macrocyclization and functionalization will find promising applications in drug discovery, such as peptide–drug conjugates (PDCs) and peptide–radionuclide conjugates (PRCs). The “click-to-release” reaction between the tetrazine and a trans-cyclooctene-modified fluorescent dye allowed us to quantify the amount of internalized peptides within living cells. Furthermore, we demonstrated an innovative high-throughput assay for quantitatively evaluating cellular penetration. We believe that this bioorthogonal cell penetration assay (BCPA) will serve as a valuable tool for the discovery and optimization of peptide drugs and probes. While initially applied to peptide permeability, this assay can be adapted to measure the cellular uptake of other molecules of interest, such as biomacromolecules, antibody–drug conjugates (ADCs), and nanomaterials. Supplementary Material